Corcept Therapeutics price target raised to $78 from $67 at Piper Sandler

Piper Sandler analyst David Amsellem raised the firm’s price target on Corcept Therapeutics (CORT) to $78 from $67 and keeps an Overweight rating on the shares following quarterly results. Looking ahead, the potential approval of relacorilant could render the current debate regarding Korlym exclusivity and exposure to generics as largely irrelevant, Piper adds.